3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
3
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Glioblastoma
1
Cranial Nerve Diseases
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Bone Neoplasms
1
Interventions
Temozolomide
10
Cyclophosphamide
10
Vincristine
9
Etoposide
6
Doxorubicin
6
Irinotecan
5
palbociclib
4
cabozantinib
4
Topotecan
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
X-Rays
3
Sirolimus
3
Phantoms, Imaging
3
Ifosfamide
3
Gemcitabine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
irinotecan sucrosofate
2
ganitumab
2
cixutumumab
2
Vemurafenib
2
Trabectedin
2
Tacrolimus
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma, Ewing
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts